z-logo
Premium
Gastrointestinal stromal tumor: 5 years later
Author(s) -
van der Zwan Sanne M.,
DeMatteo Ronald P.
Publication year - 2005
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.21419
Subject(s) - gist , medicine , pdgfra , imatinib mesylate , stromal tumor , imatinib , targeted therapy , adjuvant therapy , oncology , cancer , stromal cell , cancer research , myeloid leukemia
There is now considerable interest in gastrointestinal stromal tumor (GIST) because it can be treated effectively with a targeted molecular agent. The majority of GISTs contain an activating mutation in the KIT protooncogene or, occasionally, in the platelet‐derived growth factor‐α ( PDGFRA ) gene. Five years ago, imatinib mesylate, a specific molecular inhibitor of the protein products of these 2 genes, was applied to metastatic GIST. Approximately 80% of patients with metastatic GIST benefit from imatinib, although acquired resistance to the agent may develop. For patients with primary GIST, surgery remains the treatment of choice, and whether outcome is improved by adjuvant imatinib is currently under broad investigation. A combination of imatinib therapy and surgery also may be effective in a subset of patients with metastatic or unresectable primary GIST. In this review, the authors summarize the new multimodality approach to GIST. The integration of surgery and molecular therapy in GIST will serve as a prototype for the management of other solid tumors for which targeted agents become available. Cancer 2005. © 2005 American Cancer Society.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here